Durante, Michael A. http://orcid.org/0000-0003-3137-6847
Rodriguez, Daniel A. http://orcid.org/0000-0001-7682-6106
Kurtenbach, Stefan
Kuznetsov, Jeffim N.
Sanchez, Margaret I.
Decatur, Christina L. http://orcid.org/0000-0001-9125-1718
Snyder, Helen
Feun, Lynn G.
Livingstone, Alan S.
Harbour, J. William http://orcid.org/0000-0002-1104-9809
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA125970)
Article History
Received: 3 July 2019
Accepted: 19 December 2019
First Online: 24 January 2020
Competing interests
: J.W.H. is the inventor of intellectual property related to prognostic testing for uveal melanoma. He is a paid consultant for Castle Biosciences, licensee of this intellectual property, and he receives royalties from its commercialization. H.S. is employed by Cell IDx Inc. and owns shares in the company. The other authors declare no competing interests.